



07-09-07

Ifw

CASE 33714-US-PCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV83996095545
Express Mail Label NumberJuly 5, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
WAGNER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2005/003663

FILED: 7 APRIL 2005

U.S. APPLICATION NO: 10/599,697

35 USC §371 DATE: 5 OCTOBER 2006

FOR: PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF
AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed October 5, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding British application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: *July 5, 2007*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33714-US-PCT
APPLICATION NO.
10/599,697
APPLICANT
WAGNER ET AL.
FILING DATE
OCTOBER 5, 2006

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,057,614	10/15/91	Davis et al.	548	466	2/6/89
	AB	6,284,783	9/4/01	Zhou et al.	514	414	6/9/99
	AC	6,153,641	11/28/00	Bergstrand et al.	514	414	9/8/97
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	95/17182	6/29/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	98/04551	2/5/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	0 940 142	10/6/99	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Jordon et al., "Differential effects of protein kinase C inhibitors on chemokine production in human synovial fibroblasts", British Journal of Pharmacology, Vol. 117(6), pp. 1245-1253 (1996).
	AS	Wendling et al., "Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells -implications for multiple sclerosis", Journal of Neuroimmunology, Vol. 103(1), pp. 69-75, (2000).
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.